cmf smart presentation dr john cho.pdf
TRANSCRIPT
![Page 1: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/1.jpg)
Neoadjuvant Hemithoracic Intensity Modulated RT:
The “SMART” Approach for Malignant Pleural Mesothelioma
John Cho
29 Oct 2013
![Page 2: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/2.jpg)
Disclosures
• None
![Page 3: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/3.jpg)
Overview
• Asbestos
• Mesothelioma
• Evolution of Therapy
• SMART
![Page 4: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/4.jpg)
Asbestos
• asbestos use dates back to 4500 years ago
– Finnish pottery
• fabled fur of mythical salamander
![Page 5: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/5.jpg)
![Page 6: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/6.jpg)
![Page 7: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/7.jpg)
![Page 8: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/8.jpg)
![Page 9: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/9.jpg)
Asbestos
Chrysotile (white)
Amosite (brown)
Crocidolite (blue)
![Page 10: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/10.jpg)
![Page 11: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/11.jpg)
![Page 12: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/12.jpg)
![Page 13: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/13.jpg)
![Page 14: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/14.jpg)
![Page 15: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/15.jpg)
Resection
• early attempts at radical resection (pleurectomy/decortication, extrapleural pneumonectomy) universally disappointing
– up to 30% perioperative mortality rate
– up to 80% local recurrence rate
![Page 16: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/16.jpg)
![Page 17: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/17.jpg)
![Page 18: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/18.jpg)
Rusch. J Thorac Cardiovasc Surg 2001
![Page 19: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/19.jpg)
![Page 20: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/20.jpg)
Overall Survival
median 14 mos
![Page 21: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/21.jpg)
Survival by Nodal Status and Therapy
![Page 22: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/22.jpg)
Recurrences after Trimodality Therapy
• Recurrences
16/30 patients
Ipsilateral chest: 4
Pericardium: 1
Peritoneum: 5
Contralateral chest: 4
Chest and peritoneum: 2
![Page 23: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/23.jpg)
Recurrences after Trimodality Therapy
• Recurrences
16/30 patients
Ipsilateral chest: 4
Pericardium: 1
Peritoneum: 5
Contralateral chest: 4
Chest and peritoneum: 2
distant mets
local
![Page 24: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/24.jpg)
Rationale for Neoadjuvant Therapy
• to down stage tumour to improve resectability
– R+ R0
• to reduce local failure
– sterilize “high risk” margins
• to reduce distant failure?
![Page 25: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/25.jpg)
Neoadjuvant Hemithoracic RT
• large, complex volumes
• optimal fractionation and scheduling unknown
– 45 Gy/25 fx x 5 w then EPP at 4 weeks?
– risk of radiation pneumonitis?
![Page 26: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/26.jpg)
Study Schema
Observation
pN0-1
Adjuvant
Chemotherapy
pN2
6-12 weeks post-op
Extrapleural Pneumonectomy
1week post-RT
Neoadjuvant Hemithoracic
Intensity Modulated Radiotherapy
(25 Gy/5 fx over 1 week)
Malignant Pleural Mesothelioma
(cT1-2 cN0 M0)
Baseline Investigations
Informed Consent
Surgery for Mesothelioma After RT
![Page 27: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/27.jpg)
![Page 28: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/28.jpg)
Results
• accrual completed 10/2012
• 25 patients (19 males, 63±8 years old, 21 right sided tumors)
• all patients completed IMRT and EPP
• IMRT well tolerated with no grade 3-5 toxicity
– limited to nausea, fatigue
![Page 29: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/29.jpg)
Results
• EPP performed 6±2 days after completion of IMRT
• no deaths within 30 days of surgery or in-hospital
• at least 1 complication occurred in 18 patients during follow-up after surgery
![Page 30: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/30.jpg)
Table. Complications occurring after induction IMRT and EPP
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5Thromboembolic event 22 0 1 1 1 0
Atrial fibrillation 15 0 5 5 0 0
Wound infections 22 0 2 1 0 0
Chylothorax 23 0 0 2 0 0
Hemothorax 24 0 0 0 1 0
Wound dehiscence 21 1 2 1 0 0
Renal dysfunction 24 0 0 1 0 0
Pneumonia 24 0 0 0 1 0
Empyema 23 0 0 1 0 1
Bronchopleural fistula 25 0 0 0 0 0
![Page 31: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/31.jpg)
0 12 24 36 48 600
10
20
30
40
50
60
70
80
90
100
Overall survival
months after radiation
Su
rviv
al
(%
)
Survival by histology
0 12 24 36 48 600
10
20
30
40
50
60
70
80
90
100epithelial
biphasic
p=0.004
Months after radiation
Su
rviv
al
(%
)
(9)
(16)
62%
82%
19%
![Page 32: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/32.jpg)
Results
• median survival: 13 months
• median FU: 18 months
• overall 3-year survival: 62%
• significantly better OS for epithelial compared to biphasic MPM subtype (p=0.004)
– OS at 3 yrs, 83% for epithelial (16) and 19% for biphasics (9)
![Page 33: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/33.jpg)
Survival by nodal status
0 12 24 36 48 600
10
20
30
40
50
60
70
80
90
100ypN0-N1
ypN2
Months after radiation
Su
rviv
al
(%)
87% (10)
40% (15)
![Page 34: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/34.jpg)
Results
• 10 patients developed recurrence
– ipsilateral chest only (n=2)
– ipsilateral chest and distant sites (n=2)
– distant sites only (n=6)
![Page 35: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/35.jpg)
What we’ve learned
• short neoadjuvant hemithoracic RT followed by EPP for resectable MPM is feasible and safe
– requires high degree of cooperation and coordination between surgical and radiotherapy teams
– high rates of patient compliance
![Page 36: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/36.jpg)
• radiotherapy continue to evolve and adapt as we optimize technique
– well tolerated extending target volume to thoracic outlet and diaphragmatic attachments
– include high risk areas such as chest tube sites, retroperitoneal nodes avoid geographical misses
What we’ve learned
![Page 37: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/37.jpg)
![Page 38: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/38.jpg)
![Page 39: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/39.jpg)
![Page 40: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/40.jpg)
Acknowledgements
• Marc de Perrot
• Ron Feld
• Natasha Leighl
• Lea Dungao
• Pat Merante
![Page 41: CMF SMART presentation Dr John Cho.pdf](https://reader036.vdocument.in/reader036/viewer/2022062504/588c5dff1a28abcf208b6454/html5/thumbnails/41.jpg)
Thank you for your attention